评估胰岛素耐药性 (HOMA-IR) 对于有或没有甲状腺结节的患者:基于患者的研究
Leila Moradi1, Maryam Amir Ahmadi1, Azim Moaatamedfar2
1Department of Internal Medicine, School of Medicine, Ahvaz Jondi Shapour University of Medical Sciences, Ahvaz, Iran.
患有甲状腺结节的患者表现出更高的胰岛素抵抗 (HOMA-IR) 患病率. 这项研究发现,与对照人群相比,甲状腺结节患者的HOMA-IR水平显著升高.
科学领域:
- 内分泌学 在内分泌学.
- 代谢健康 代谢健康
- 甲状腺学 甲状腺学
背景情况:
- 甲状腺结节是常见的内分泌发现.
- 胰岛素抵抗是代谢障碍的一个关键因素.
- 甲状腺结节和胰岛素抵抗之间的关系需要进一步研究.
研究的目的:
- 为了确定患有甲状腺结节的患者胰岛素抵抗 (HOMA-IR) 的患病率.
- 为了比较患有甲状腺结核和没有甲状腺结核的患者之间的HOMA-IR水平.
主要方法:
- 一项病例对照研究涉及86名甲状腺结节患者和43名对照患者.
- 所有参与者都具有正常的甲状腺刺激激素 (TSH) 水平.
- 胰岛素耐药性是使用恒温模式对胰岛素耐药性评估 (HOMA-IR) 指数进行评估的,HOMA-IR ≥2.5表示胰岛素耐药性.
主要成果:
- 甲状腺结节组中的平均HOMA-IR显著高于对照组中的平均HOMA-IR (3.02 ± 1.92) (1.10 ± 1.55;P < 0.001).
- 在57.0%的甲状腺结节患者中观察到胰岛素耐药性,而对照组中则为9.3% (P < 0.0001).
- 在甲状腺结节组中,腰围,体重指数,禁食血糖,甘油三,胆固醇,LDL,HDL和胰岛素的水平较高.
结论:
- 胰岛素抵抗和甲状腺结节的存在之间存在显著的关联.
- 患有甲状腺结节的患者表现出更高程度的胰岛素抵抗.
更多相关视频
08:13Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
07:30Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
相关概念视频
Synthesis and Regulation of Thyroid Hormones
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Functions of Thyroid Hormones
TH is indispensable for the normal development and maturation of the skeletal, muscular, and nervous systems during fetal and childhood growth. It facilitates bone mineral turnover and regulates protein synthesis in developing tissues, contributing significantly to overall growth and...
Hypoglycemia and Glucagon
Oral Hypoglycemic Agents: Biguanides and Glitazones
Insulin: The Receptor and Signaling Pathways
